Advanced search
Publication Cover
Cancer Biology & Therapy Volume 19, 2018 - Issue 5
Submit an article Journal homepage
882
Views
0
CrossRef citations to date
0
Altmetric
Bedside to Bench Report

First-line treatment of apatinib in elderly patient of advanced gastric carcinoma: A case report of NGS-driven targeted therapy

Yan YangDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, People's Republic of ChinaORCID Iconhttp://orcid.org/0000-0003-0887-2770View further author information
ORCID Icon,
Wuqiong ZhangDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, People's Republic of ChinaView further author information
,
Jinghao YaoDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, People's Republic of ChinaView further author information
,
Jing LiuDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, People's Republic of ChinaView further author information
,
Shukui QinDepartment of Medical Oncology, PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, People's Republic of ChinaView further author information
&
Qiong WuDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, People's Republic of ChinaCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-0677-7737View further author information
ORCID Icon
Pages 355-358 | Received 11 Oct 2017, Accepted 29 Dec 2017, Published online: 22 Feb 2018

References

  • Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32. doi.org/10.3322/caac.21338. PMID:26808342.
  • Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991–7. doi.org/10.1200/JCO.2006.06.8429. PMID:17075117.
  • Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46. doi.org/10.1056/NEJMoa073149. PMID:18172173.
  • Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. doi.org/10.1016/S0140-6736(10)61121-X. PMID:20728210.
  • Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35. doi.org/10.1016/S1470-2045(14)70420-6. PMID:25240821.
  • Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, et al. Randomized, Double-Blind, Placebo-Controlled Phase III trial of Apatinib in patients with Chemotherapy-Refractory advanced or metastatic Adenocarcinoma of the stomach or Gastroesophageal junction. J Clin Oncol. 2016;34(13):1448–54. doi.org/10.1200/JCO.2015.63.5995. PMID:26884585.
  • Scott AJ, Messersmith WA, Jimeno A. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors. Drugs Today (Barc). 2015;51(4):223–9. doi.org/10.1358/dot.2015.51.4.2320599. PMID:26020064.
  • Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9. doi.org/10.1038/nature13480. PMID:25079317.
  • Gonin-Laurent N, Gibaud A, Huygue M, Lefevre SH, Le Bras M, Chauveinc L, Sastre-Garau X, Doz F, Lumbroso L, Chevillard S, et al. Specific TP53 mutation pattern in radiation-induced sarcomas. Carcinogenesis. 2006;27(6):1266–72. doi.org/10.1093/carcin/bgi356. PMID:16492679.
  • Kim SJ, Lee HW, Baek JH, Cho YH, Kang HG, Jeong JS, Song J, Park HS, Chun KH. Activation of nuclear PTEN by inhibition of Notch signaling induces G2/M cell cycle arrest in gastric cancer. Oncogene. 2016;35(2):251–60. doi.org/10.1038/onc.2015.80. PMID:25823029.
  • Suzuki S, Dobashi Y, Hatakeyama Y, Tajiri R, Fujimura T, Heldin CH, Ooi A. Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-beta phosphorylation, and microvessel density in gastric cancer. BMC Cancer. 2010;10:659. doi.org/10.1186/1471-2407-10-659. PMID:21118571.
  • Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol. 2013;31(9):1219–30. doi.org/10.1200/JCO.2012.46.2762. PMID:23401453.
  • Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortés J, Delmar PR, et al. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer. 2013;108(5):1052–60. doi.org/10.1038/bjc.2013.69. PMID:23422754.
  • Miles D, Cameron D, Bondarenko I, Manzyuk L, Alcedo JC, Lopez RI, Im SA, Canon JL, Shparyk Y, Yardley DA, et al. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. Eur J Cancer. 2017;70:146–55. doi.org/10.1016/j.ejca.2016.09.024. PMID:27817944.
  • Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, Peng Yong W, Langer B, Delmar P, Scherer SJ, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012;30(17):2119–27. doi.org/10.1200/JCO.2011.39.9824. PMID:22565005.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.